You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 1, 2024

Claims for Patent: 9,592,288

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,592,288

Title:	Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
Abstract:	The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
Inventor(s):	Schultz; Peter (La Jolla, CA), Lairson; Luke (San Diego, CA), Deshmukh; Vishal (La Jolla, CA), Lyssiotis; Costas (Boston, MA)
Assignee:	The Scripps Research Institute (La Jolla, CA) IRM LLC (Hamilton, BM)
Application Number:	13/985,342
Patent Claims:	1. A method of enhancing a therapeutic effect of an immunomodulatory agent that is effective in treating multiple sclerosis, the method comprising: administering to a human subject having multiple sclerosis the immunomodulatory agent and a muscarinic receptor antagonist; thereby enhancing the therapeutic effect of the immunomodulatory agent in treatment of multiple sclerosis. 2. The method of claim 1, wherein the muscarinic receptor antagonist is selected from atropine, benztropine, carbetapentane, clemastine, dicylomine, diphemanil, glycopyrrolate, hyoscyamine, ipratropium, methantheline, methylatropine, octatropine, oxybutynin, propantheline, propiverine, scopolamine, tiotropium, tolterodine, and salts thereof. 3. The method of claim 1, wherein the immunomodulatory agent is fingolimod (FTY720), interferon beta-1a, interferon beta-1b, glatiramer acetate, mitoxantrone, or natalizumab. 4. The method of claim 1, wherein: (i) each of the immunomodulatory agent and the muscarinic receptor antagonist is administered at a therapeutically effective dose; or (ii) the muscarinic receptor antagonist is administered at a therapeutically effective dose and the immunomodulatory agent is administered at a subtherapeutic dose; or (iii) each of the immunomodulatory agent and the muscarinic receptor antagonist is administered at a subtherapeutic dose. 5. The method of claim 1, wherein the immunomodulatory agent and the muscarinic receptor antagonist are administered systemically. 6. The method of claim 1, wherein the immunomodulatory agent and the muscarinic receptor antagonist are administered sequentially. 7. The method of claim 1, wherein the immunomodulatory agent and the muscarinic receptor antagonist are administered concurrently. 8. The method of claim 1, wherein the muscarinic receptor antagonist is selected from atropine, benztropine, carbetapentane, clemastine, ipratropium, oxybutynin, propiverine, and scopolamine. 9. The method of claim 1, wherein the muscarinic receptor antagonist is benztropine. 10. The method of claim 1, wherein the immunomodulatory agent is a monoclonal antibody. 11. The method of claim 10, wherein the immunomodulatory agent is natalizumab, rituximab, daclizumab, or alemtuzumab. 12. The method of claim 1, wherein the immunomodulatory agent is selected from an interferon-.beta. and fingolimod. 13. The method of claim 1, wherein the immunomodulatory agent is an S1P agonist. 14. The method of claim 13, wherein the immunomodulatory agent is fingolimod.

Details for Patent 9,592,288

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	BETASERON	interferon beta-1b	For Injection	103471	07/23/1993	⤷ Try a Trial	2031-02-18
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	05/17/1996	⤷ Try a Trial	2031-02-18
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	05/28/2003	⤷ Try a Trial	2031-02-18
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.